Clinical trials: Flu
Influenza A H3N2
Study Examining PrEP-001 in Healthy Subjects
Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.
- Trial name
- NCT03220048
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza A
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the…
- Trial name
- NCT01701752
- Testing
- FP-01.1 + TIV, FP-01.1-Adjuvant + TIV, Adjuvant + TIV
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Influenza
Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)
The clinical trial was conducted in Jintan City of Jiangsu Province, China in May, 2006. The purpose of the clinical trial was to evaluate the safety and immunogenicity against Hualan's Influenza Vaccine (Split Virion)…
- Trial name
- NCT01554813
- Testing
- Influenza split vaccine of 15 μg HA, Influenza split vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Avian Influenza
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule.
- Trial name
- ICC H5 (NCT01698060)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vaxart
Flu, Cold
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula
The goal of this interventional clinical trial is to test the effectiveness of enhancing immunity in newly born infants fed with Feihe investigational formula product containing Lactoferrin fortified with HMO.
- Trial name
- NCT06158659
- Testing
- Feihe Investigational Formula, Control Formula, Breastfeeding
- Where
- 3 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19, Influenza
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
The goal is to evaluate the in-depth immunogenicity analysis (including B-cell and T-cell response) of coadministration of a omicron-containing COVID-19 vaccine and influenza vaccine among healthy adults during 2023-24 season.
- Conditions
- COVID-19, Influenza, Vaccine Reaction, Contaminant Injected
- Trial name
- NCT06091410
- Testing
- Omicron-containing COVID-19 vaccine, influenza vaccine
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Catholic Kwandong University
Grippe, Influenza
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza.
- Conditions
- Grippe, Influenza, Vaccines
- Trial name
- NCT06179446
- Testing
- pdmFlu vaccine, Licensed influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Pfizer
A/Vietnam/H5N1 Influenza Virus
Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant
The main purpose of this study is to assess the usability of long-term stored H5N1 antigen and adjuvant. The study is designed to assist in stockpile management by assessing the safety, reactogenicity, and immunogenicity…
- Trial name
- NCT02680002
- Testing
- 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Influenza
Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults
This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.
- Trial name
- VAX128-01 (NCT01172054)
- Testing
- VAX128
- Where
- 2 sites in United States
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza A Subtype H5N1 Infection
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pandemic influenza.
- Trial name
- NCT01657929
- Testing
- H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R)
- Where
- 3 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Decreased Immunologic Activity [PE], Influenza
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients.
- Conditions
- Decreased Immunologic Activity [PE], Influenza, Rejection
- Trial name
- NCT01298102
- Testing
- Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Response of Viral Infection to Woodsmoke
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
This study is focused on the pathophysiology underlying the association between exposure to particulate pollutants and risk for/response to viral infection.
- Trial name
- Woodsies (NCT02183753)
- Testing
- wood smoke, clean air
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza, Orthomyxoviridae Infections
A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine
This study is designed to generate clinical data as outlined in the Note for Guidance on harmonization requirements for influenza vaccine marketing authorization by the European Medicines Agency.
- Trial name
- NCT00491257
- Testing
- Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
- Where
- 2 sites in United Kingdom
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults
The aim of the study is to assess the safety profile of a quadrivalent influenza vaccine (QIV) and to demonstrate that 3 different industrial lots of QIV induce an equivalent immune response in children/adolescents (9 to 17 years…
- Trial name
- NCT01481454
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated), 2011 to 2012 Trivalent Influenza Vaccine
- Where
- 6 sites in Australia, Philippines
- Volunteers
- 1,701 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Breast Cancer, Lung Cancer
Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Infections due to influenza and pneumococcus can be very serious and cause death. Anyone can get these infections. However, some people are at greater risk from the disease, including people 65 and older, the very young, and…
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00741039
- Testing
- inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Seasonal Influenza
Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers
The present study will evaluate the safety in healthy people aged 1- 45 years (male and female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza vaccine till the 30-days follow-up period.
- Trial name
- NCT01123954
- Testing
- Seasonal flu vaccine
- Where
- Vietnam
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Acute Upper Respiratory Tract Infection, Influenza
Kagocel® for the Prevention of ARVI and Influenza in Young People
This study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in the incidence of diseases in Russia in 2018 (epidemiology: the number of cases…
- Conditions
- Acute Upper Respiratory Tract Infection, Influenza, Respiratory Viral Infection
- Trial name
- NCT04626622
- Testing
- Kagocel, No one
- Where
- Russia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Nosocomial Infections
Nosocomial Respiratory Virus Infection
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing…
- Trial name
- NOSOVIRUS (NCT06643039)
- Testing
- Nasopharyngeal swab, Questionnaire
- Where
- 6 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Influenza
Eldery High Dose TIV 2005
The purpose of this study is to compare a new higher-dose influenza virus vaccine to the standard dose vaccine in elderly adults who can walk.
- Trial name
- NCT00115531
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.